Small Molecules that Correct RNA Splicing

At Skyhawk Therapeutics we use proprietary structural, kinetic, and computational models to invent small molecules that correct splicing in RNA, targeting some of the world's most intractable diseases

PARTNERS

IN THE NEWS

Merck doubles down on Skyhawk's tech to drug RNA, promising

$600M per autoimmune, metabolic target

When Merck signed on to discover candidates against neurodegeneration and cancer last July, Biogen was just expanding the list of neuro targets they want to go after. Now Merck is coming back for its own round two, adding autoimmune and metabolic diseases to the menu.

The 20 under 40: Inside the next generation of biopharma leaders

U-2 Dragon Lady, one of the conference rooms at Skyhawk Therapeutics’ office in Waltham, MA, is named after both

the American single-jet engine, high altitude reconnaissance aircraft and founder Kathleen McCarthy.

Skyhawk Therapeutics boosts Merck collab pact with added targets, upfront and biobucks

Merck has decided to double down on its research pact with startup Skyhawk Therapeutics as it expands the deal to now also cover autoimmune and metabolic diseases.

IN THE NEWS

Merck doubles down on Skyhawk's tech to drug RNA, promising

$600M per autoimmune, metabolic target

When Merck signed on to discover candidates against neurodegeneration and cancer last July, Biogen was just expanding the list of neuro targets they want to go after. Now Merck is coming back for its own round two, adding autoimmune and metabolic diseases to the menu.

The 20 under 40: Inside the next generation of biopharma leaders

U-2 Dragon Lady, one of the conference rooms at Skyhawk Therapeutics’ office in Waltham, MA, is named after both

the American single-jet engine, high altitude reconnaissance aircraft and founder Kathleen McCarthy.

The Endpoints 11: Here are some of the most promising startups in biotech.

And Covid-19 isn't going to stop them

"Go international from the beginning"

WHAT WE DO

Our proprietary small molecule platform targets accelerates the discovery and development of drugs that correct RNA mis-splicing across a broad range of disease types:

ONCOLOGY

NEUROLOGY

INFLAMMATORY

INFECTIOUS

RARE

NEUROMUSCULAR

& METABOLIC

Skyhawk Therapeutics, Inc.

35 Gatehouse Drive

 

Waltham, MA 02451

United States of America

 

info@skyhawktx.com

 

Tel: 617.858.0041

Skyhawk Therapeutics Europe GmbH

 

Basel Technology Park

Hochbergerstrasse 60C

Basel 4057

Switzerland

 swiss-info@skyhawktx.com

Tel: +41 (0) 61 638 23 50

  • LinkedIn - White Circle
  • Twitter - White Circle

Copyright 2019 SKYHAWK THERAPEUTICS, INC.

SKYHAWK® and SKYSTAR® are registered trademarks of Skyhawk Therapeutics, Inc. in the US and other countries.